Cargando…

Oncometabolite D-2-hydroxyglutarate—dependent metabolic reprogramming induces skeletal muscle atrophy during cancer cachexia

Cancer cachexia is characterized by weight loss and skeletal muscle wasting. Based on the up-regulation of catabolism and down-regulation of anabolism, here we showed genetic mutation-mediated metabolic reprogramming in the progression of cancer cachexia by screening for metabolites and investigatin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Xinting, Hao, Juan, Zhang, Hong, Chi, Mengyi, Wang, Yaxian, Huang, Jinlu, Xu, Rong, Xincai, Zhao, Xin, Bo, Sun, Xipeng, Zhang, Jianping, Zhou, Shumin, Cheng, Dongdong, Yuan, Ting, Ding, Jun, Zheng, Shuier, Guo, Cheng, Yang, Quanjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518016/ https://www.ncbi.nlm.nih.gov/pubmed/37741882 http://dx.doi.org/10.1038/s42003-023-05366-0

Ejemplares similares

The oncometabolite 2-hydroxyglutarate produced by mutant IDH1 sensitizes cells to ferroptosis
por: Wang, Tian-Xiang, et al.
Publicado: (2019)

Human Phosphoglycerate Dehydrogenase Produces the Oncometabolite d-2-Hydroxyglutarate
por: Fan, Jing, et al.
Publicado: (2014)

The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway
por: Carbonneau, Mélissa, et al.
Publicado: (2016)

The Enzymology of 2-Hydroxyglutarate, 2-Hydroxyglutaramate and 2-Hydroxysuccinamate and Their Relationship to Oncometabolites
por: Hariharan, Vivek A., et al.
Publicado: (2017)

Another small molecule in the oncometabolite mix: L-2-Hydroxyglutarate in kidney cancer
por: Shim, Eun-Hee, et al.
Publicado: (2015)

Lactonization of the Oncometabolite D-2-Hydroxyglutarate Produces a Novel Endogenous Metabolite
por: Berger, Raffaela S., et al.
Publicado: (2021)

D2HGDH-mediated D2HG catabolism enhances the anti-tumor activities of CAR-T cells in an immunosuppressive microenvironment
por: Yang, Quanjun, et al.
Publicado: (2022)

Human phosphoglycerate dehydrogenase produces the oncometabolite D-2-hydroxyglutarate and promotes histone methylation
por: Fan, Jing, et al.
Publicado: (2014)

The Emerging Role of D-2-Hydroxyglutarate as an Oncometabolite in Hematolymphoid and Central Nervous System Neoplasms
por: Rakheja, Dinesh, et al.
Publicado: (2013)

Registered report: Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases
por: Evans, Brad, et al.
Publicado: (2015)

Imaging 2-hydroxyglutarate and other brain oncometabolites pertinent to critical genomic alterations in brain tumors
por: Thomas, Teena, et al.
Publicado: (2023)

The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas
por: Mu, Luyan, et al.
Publicado: (2018)

Intracerebral Distribution of the Oncometabolite d-2-Hydroxyglutarate in Mice Bearing Mutant Isocitrate Dehydrogenase Brain Tumors: Implications for Tumorigenesis
por: Pickard, Amanda J., et al.
Publicado: (2016)

The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivo
por: Suijker, Johnny, et al.
Publicado: (2015)

The oncometabolite R-2-hydroxyglutarate dysregulates the differentiation of human mesenchymal stromal cells via inducing DNA hypermethylation
por: Liu, Lizhen, et al.
Publicado: (2021)

The oncometabolite R-2-hydroxyglutarate activates NF-κB-dependent tumor-promoting stromal niche for acute myeloid leukemia cells
por: Chen, Jing-Yi, et al.
Publicado: (2016)

Linalool Prevents Cisplatin Induced Muscle Atrophy by Regulating IGF-1/Akt/FoxO Pathway
por: Zhang, Hong, et al.
Publicado: (2020)

Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells
por: Hujber, Zoltán, et al.
Publicado: (2017)

Oncometabolite D-2-Hydroxyglutarate enhances gene silencing through inhibition of specific H3K36 histone demethylases
por: Janke, Ryan, et al.
Publicado: (2017)

Metabolomic analysis identifies differentially produced oral metabolites, including the oncometabolite 2-hydroxyglutarate, in patients with head and neck squamous cell carcinoma
por: Mukherjee, Pranab K., et al.
Publicado: (2016)

Accumulation of oncometabolite D-2-Hydroxyglutarate by SLC25A1 inhibition: A metabolic strategy for induction of HR-ness and radiosensitivity
por: Xiang, Kexu, et al.
Publicado: (2022)

Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells
por: Li, Luyuan, et al.
Publicado: (2015)

A Drosophila model of combined D-2- and L-2-hydroxyglutaric aciduria reveals a mechanism linking mitochondrial citrate export with oncometabolite accumulation
por: Li, Hongde, et al.
Publicado: (2018)

Renal oncometabolite L-2-hydroxyglutarate imposes a block in kidney tubulogenesis: Evidence for an epigenetic basis for the L-2HG-induced impairment of differentiation
por: Taub, Mary, et al.
Publicado: (2022)

Oncometabolites and the response to radiotherapy
por: Xiang, Kexu, et al.
Publicado: (2020)

Notch Signaling Mediates Skeletal Muscle Atrophy in Cancer Cachexia Caused by Osteosarcoma
por: Mu, Xiaodong, et al.
Publicado: (2016)

The emerging role of fumarate as an oncometabolite
por: Yang, Ming, et al.
Publicado: (2012)

Oncometabolites: tailoring our genes
por: Nowicki, Stefan, et al.
Publicado: (2015)

Kynurenine: an oncometabolite in colon cancer
por: Venkateswaran, Niranjan, et al.
Publicado: (2020)

Metabolic Rewiring and the Characterization of Oncometabolites
por: Beyoğlu, Diren, et al.
Publicado: (2021)

Regulation of Skeletal Muscle Atrophy in Cachexia by MicroRNAs and Long Non-coding RNAs
por: Chen, Rui, et al.
Publicado: (2020)

Lithium Chloride Protects against Sepsis-Induced Skeletal Muscle Atrophy and Cancer Cachexia
por: Lee, Ji-Hyung, et al.
Publicado: (2021)

A chemoproteomic portrait of the oncometabolite fumarate
por: Kulkarni, Rhushikesh A., et al.
Publicado: (2019)

Oncometabolites: A new insight for oncology
por: Khatami, Fatemeh, et al.
Publicado: (2019)

Superior antitumor immunotherapy efficacy of kynureninase modified CAR-T cells through targeting kynurenine metabolism
por: Yang, Quanjun, et al.
Publicado: (2022)

Cancer cachexia and skeletal muscle atrophy in clinical studies: what do we really know?
por: Dolly, Adeline, et al.
Publicado: (2020)

SLC14A1 prevents oncometabolite accumulation and recruits HDAC1 to transrepress oncometabolite genes in urothelial carcinoma
por: Chan, Ti-Chun, et al.
Publicado: (2020)

The Roles of 2-Hydroxyglutarate
por: Du, Xin, et al.
Publicado: (2021)

Oncometabolites: Unconventional triggers of oncogenic signalling cascades
por: Sciacovelli, Marco, et al.
Publicado: (2016)

Oncometabolite induced primary cilia loss in pheochromocytoma
por: O’Toole, Samuel M, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_b5d828uc44gvtudvch1vd4a5ci